Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 15, 2025 07:30 ET | Source: Kailera Therapeutics, Inc.

Hengrui Pharma and Kailera Therapeutics Report Positive Topline Data from Phase 3 Obesity Trial in China of Dual GLP-1/GIP Receptor Agonist HRS9531

Hengrui and Kailera announced positive topline data from Hengrui’s Phase 3 clinical trial of HRS9531, a novel dual GLP-1/GIP receptor agonist, in obesity.
June 16, 2025 07:00 ET | Source: Kailera Therapeutics, Inc.

Jiangsu Hengrui Pharmaceuticals and Kailera Therapeutics Announce Clinical Data Presentations at the American Diabetes Association 85th Scientific Sessions

Hengrui Pharma and Kailera today announced the presentation of six abstracts at the 85th Scientific Sessions of the American Diabetes Association (ADA).
June 05, 2025 07:30 ET | Source: Kailera Therapeutics, Inc.

Kailera Therapeutics Appoints Adam Koppel and Christopher Hite to Board of Directors

Kailera Therapeutics today announced the appointments of Adam Koppel and Christopher Hite to its Board of Directors.
January 27, 2025 07:45 ET | Source: Kailera Therapeutics, Inc.

Kailera Therapeutics Appoints Jamie Coleman as Chief Commercial Officer

Kailera Therapeutics today announced the appointment of Jamie Coleman, former U.S. Brand Leader for Zepbound, as Chief Commercial Officer.
January 13, 2025 08:00 ET | Source: Kailera Therapeutics, Inc.

Jiangsu Hengrui Pharmaceuticals and Kailera Therapeutics Report Positive Topline Data from 8 mg Dose of Phase 2 Obesity Trial of GLP-1/GIP Receptor Dual Agonist HRS9531

Kailera and Hengrui Pharma announced positive topline data from the 8 mg dose of Hengrui’s Phase 2 clinical trial of HRS9531, a GLP-1/GIP dual agonist.
January 08, 2025 08:05 ET | Source: Kailera Therapeutics, Inc.

Kailera Therapeutics Appoints Laurie Stelzer as Chief Financial Officer

Kailera Therapeutics today announced the appointment of Laurie Stelzer as Chief Financial Officer.
January 06, 2025 08:15 ET | Source: Kailera Therapeutics, Inc.

Kailera Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference

Ron Renaud, Kailera's President and Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025.
November 12, 2024 08:00 ET | Source: Kailera Therapeutics, Inc.

Kailera Therapeutics Appoints Scott M. Akamine as Chief Legal Officer

Today, Kailera Therapeutics announced the appointment of Scott Akamine as Chief Legal Officer.
October 01, 2024 07:00 ET | Source: Kailera Therapeutics, Inc.

Kailera Therapeutics Launches with $400 Million Series A Financing to Advance Portfolio of Next-Generation Therapies for Obesity and Related Conditions

Kailera today announced its launch as a clinical-stage biopharmaceutical company advancing next-generation therapies for obesity and related conditions.